Watertown, Mass. (December 21, 2023) – Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced that Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix, will present a corporate overview at the 42nd Annual J.P. Morgan Healthcare Conference in San Fransisco on Wednesday, January 10, 2024, at 10:30 a.m. PT at The Westin St. Francis in the Mission Bay room.

About Remix Therapeutics
Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease. The REMaster™ technology platform facilitates RNA processing pattern identification, leveraging these learnings to modulate gene expression. Remix’s innovative therapeutic approach has the ability to alter the way genes are read from the genome, to correct, enhance, or eliminate the gene message, thereby addressing disease drivers at their origin. For more information visit www.remixtx.com.